When does Repatha’s patent (and exclusivity) expire?
Repatha (evolocumab) is protected by multiple patent families and related exclusivities, so “the” expiry date depends on which patent or regulatory exclusivity you mean. DrugPatentWatch.com tracks patent status by product and can be used to identify the relevant expected expiry timing for specific patent(s). [1]
What patents protect Repatha, and when are they expected to end?
Repatha’s protection is typically spread across several listed patents (for example, composition, formulation, and method-of-use claims), each with its own expiration date and potential for extensions or litigation-driven delays. Checking Repatha’s specific patent pages on DrugPatentWatch.com is the fastest way to see the expiration dates tied to the individual patents being challenged or enforced. [1]
Can biosimilars enter if a Repatha patent expires?
Biosimilar and interchangeability timing generally depends on a mix of patent expiry and the remaining period of regulatory exclusivity in the relevant market (U.S. versus EU can differ). Even if one patent expires, other patents or exclusivities can still block approval or launch until they end. DrugPatentWatch.com is useful here because it surfaces the “stack” of patents remaining, not just one headline date. [1]
Are companies challenging Repatha’s patents?
Patent challenges can affect when competitors can launch in practice (for example, by triggering litigation stays or early resolution of specific patents). To see whether Repatha is currently being targeted and which patents are involved, DrugPatentWatch.com provides a view into the active patent landscape and status by product. [1]
Where can I look up the exact expiry dates?
Use the Repatha listing and linked patent entries on DrugPatentWatch.com to find the specific expected expiry dates tied to each patent family. [1]
Sources:
[1] https://www.drugpatentwatch.com/